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Introduction
============

Endothelial cells form a semipermeable barrier that separates circulating blood elements from underlying tissue ([@bib46]; [@bib43]). Cell shape and, consequently, barrier function are maintained by a balance of forces ([@bib14]; [@bib70]). Centripetally directed tension is generated by actomyosin motor function ([@bib35]; [@bib60]; [@bib24], [@bib25]; [@bib23]; [@bib27]; [@bib49]; [@bib4]), and is opposed by adhesive proteins at the cell--cell border and focal adhesions at the cell--matrix border ([@bib16]; [@bib43]; [@bib75]; [@bib3]). Inflammatory mediators, which act by elevating \[Ca^2+^\]i, both increase tension and decrease adhesion important for the generation of focal intercellular gaps that form a paracellular pathway to promote fluid, solute, and protein permeability ([@bib46]; [@bib43]). Physiological transitions in cytosolic calcium (\[Ca^2+^\]i) through store-operated calcium entry pathways trigger gap formation, although \[Ca^2+^\]i-dependent targets that mediate the change in cell shape are poorly understood.

Inflammatory \[Ca^2+^\]i agonists only increase permeability in the absence of a rise in cAMP ([@bib9]; [@bib10]; [@bib44]; [@bib48]; [@bib61]; [@bib1]; [@bib52]). cAMP-elevating agents improve constitutive barrier function and prevent the endothelial cell disruption that occurs in response to a rise in \[Ca^2+^\]i. Moreover, either inhibition of cAMP synthesis or its protein kinase (e.g., PKA) is sufficient to decrease adhesion and increase permeability ([@bib61]; [@bib63]), suggesting that cAMP primarily regulates sites of cell--cell tethering. These findings bring into question the independent roles of \[Ca^2+^\]i and cAMP in endothelial cell barrier disruption. Results from cloning and expression of a calcium-inhibited adenylyl cyclase (type 6 adenylyl cyclase \[AC~6~\][\*](#fn1){ref-type="fn"}) in nonexcitable cells provided a plausible mechanism through which inflammatory \[Ca^2+^\]i agonists could decrease cAMP ([@bib74]). Endothelial cells express AC~6~ as determined by in vivo ([@bib12]; [@bib33]) and in vitro assays ([@bib40],[@bib41]; [@bib63], [@bib64], [@bib65]; unpublished data). Submicromolar calcium concentrations decrease cAMP accumulation by ∼30% in endothelial cell membranes ([@bib63]), and activation of store-operated calcium entry decreases cAMP and PKA activity 30--50% in intact cells ([@bib63], [@bib64], [@bib65]; unpublished data). Thus, calcium inhibition of AC~6~ may importantly contribute to endothelial cell gap formation.

Evidence for regulation of endothelial cell barrier function by AC~6~ is indirect and has been hampered by the inability to specifically control cAMP concentrations within a physiologically relevant range. A mechanism(s) accounting for calcium inhibition of AC~6~ is unresolved ([@bib30]; [@bib29]), although calcium inhibition does not require calmodulin or other calcium binding proteins ([@bib6]). Recent studies suggest the presence of two distinct calcium binding sites on AC~6~, with apparent high and low affinities ([@bib30]; [@bib29]). Presumably the high affinity binding site accounts for enzyme calcium inhibition, because even calcium-insensitive isoforms of AC possess a low affinity binding site that inhibits enzyme activity at millimolar calcium concentrations. Structural assignment of the high affinity binding site is incomplete, making site-directed mutagenesis an untenable approach to evaluate the physiological role of AC~6~.

[@bib21] recently developed an adenovirus that expresses a calcium calmodulin--stimulated (AC~8~) enzyme. In their studies, adenovirus infection resulted in significant AC~8~ expression in the excitable GH~4~C~1~ cell type. Enzyme activity was intimately regulated by calcium entry through store-operated calcium entry pathways, relatively insensitive to regulation by calcium entry through voltage-gated calcium channels, and not stimulated by calcium release from intracellular stores. Their findings indicated that calcium-sensitive ACs functionally colocalize with store-operated calcium entry pathways ([@bib19], [@bib20], [@bib22]), and also demonstrated that AC~8~ expression may represent a tenable approach to reversing the endogenous calcium inhibition of AC~6~. Presently, we used the adenoviral construct that expresses AC~8~ to examine the physiological role of endogenously expressed AC~6~ in nonexcitable endothelial cells. Our results indicate that thrombin-induced gap formation only proceeds when a rise in \[Ca^2+^\]i inhibits AC~6~ and is not observed when a rise in \[Ca^2+^\]i stimulates AC~8~. These results provide the first direct evidence that calcium inhibition of AC~6~ plays a central, dominant role in regulation of intercellular gap formation.

Results
=======

Thrombin-induced \[Ca^2+^\]i responses in lung macro- and microvascular endothelium
-----------------------------------------------------------------------------------

Lung macro- and microvascular endothelial cells exhibit distinct \[Ca^2+^\]i regulatory properties ([@bib64]), although the relative \[Ca^2+^\]i responses to G~q~-linked agonists are poorly understood. We therefore used pulmonary artery (PAECs) and microvascular endothelial cells (PMVECs) to examine thrombin-activated \[Ca^2+^\]i signaling. In PAECs, thrombin induced a typical peak in \[Ca^2+^\]i that was due to calcium release from intracellular stores, followed by calcium entry across the cell membrane ([Fig. 1](#fig1){ref-type="fig"} A). Thrombin-induced calcium release occurs in response to inositol 1,4,5-trisphosphate (InsP~3~) production that activates InsP~3~ receptors in the endoplasmic reticulum; the magnitude of this release phase is not influenced by acutely reducing extracellular calcium ([@bib64]). Calcium entry across the cell membrane occurs after calcium store depletion due to activation of store- and receptor-operated calcium channels ([@bib54]).

###### 

**Thrombin produces a bell shape \[Ca^2^** ^+^ **\]i dose-dependent curve in PAECs.** (A) Individual traces reveal that thrombin initiates \[Ca^2+^\]i signaling at concentrations below 0.01 U/ml, and reaches a maximal response at 1 U/ml. Higher thrombin concentrations reduce both calcium release (peak height) and entry (sustained plateau) phases. Indeed, in response to 100 U/ml thrombin, \[Ca^2+^\]i drops below constitutive levels during the "entry" phase, indicating pronounced inhibition of entry or stimulation of extrusion. Units on the y axis scale represent the ratio of calcium-bound (340 nm) to -unbound (380 nm) wavelengths for fura-2 fluorescence. Calcium release (B and D) and entry (C and D) phases are summarized, and are representative of *n* = 3--8/treatment. Area (AU, arbitrary units) on the y axis scale represents the relative area under the curve (e.g., above baseline values) generated during the Ca^2+^ entry phase.
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Dose response curves revealed that 1 U/ml thrombin maximally activated both calcium release and entry in PAECs, indicating direct coupling between calcium store depletion and calcium entry through store-operated calcium entry pathways ([Fig. 1](#fig1){ref-type="fig"}, B--D). The correlation between calcium release and entry was exact until 1 U/ml thrombin. At higher thrombin concentrations (100 U/ml), however, calcium release was reduced to 30% of its maximal response and calcium entry was 25% below basal levels. The thrombin \[Ca^2+^\]i dose response was bell shaped, suggesting that higher thrombin concentrations, in particular, activated interrelated regulatory pathways. These findings are generally compatible with thrombin\'s simultaneous activation of multiple signaling pathways ([@bib45]). Because the correlation between calcium release and entry was not apparent at high thrombin concentrations, these data suggest that thrombin activated feedback inhibition of calcium entry channels.

The thrombin-induced \[Ca^2+^\]i responses were different in PMVECs than in PAECs. Thrombin induced a sigmoidal \[Ca^2+^\]i dose response curve in PMVECs, both in calcium release and entry ([Fig. 2](#fig2){ref-type="fig"}). There was good association between calcium release and entry over the entire dose range ([Fig. 2](#fig2){ref-type="fig"} D), generally compatible with the mechanism of store-operated calcium entry. PMVECs were more sensitive to thrombin than were PAECs. Even though thrombin did not initiate a \[Ca^2+^\]i rise in PMVECs until 0.1 U/ml (versus 0.01 U/ml in PAECs), the microvascular cell dose response curve was left shifted, indicating greater thrombin sensitivity; in PMVECs the EC~50~ = 0.05 U/ml and in PAECs the EC~50~ = 0.1 U/ml.

###### 

**Thrombin produces a sigmoidal \[Ca^2^** ^+^ **\]i dose-dependent curve in PMVECs.** (A) Individual traces reveal that thrombin initiates \[Ca^2+^\]i signaling at concentrations near 0.01 U/ml, and reaches a maximal response near 0.1 U/ml. This maximal \[Ca^2+^\]i response is sustained after application of higher thrombin concentrations. Indeed, the \[Ca^2+^\]i response to 0.1 and 10 U/ml thrombin are nearly identical. Units on the y axis scale represent the ratio of calcium-bound (340 nm) to -unbound (380 nm) wavelengths for fura-2 fluorescence. Calcium release (B and D) and entry (C and D) phases are summarized, and are representative of *n* = 3--4/treatment. Area (AU, arbitrary units) on the y axis scale represents the relative area under the curve (e.g., above baseline values) generated during the Ca^2+^ entry phase.
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Calcium release and entry coupling was not similar between PMVECs and PAECs. Even though good association between calcium release and entry was observed in PMVECs, these findings are incompatible with the notion that store-operated calcium entry pathways represent the predominant mode of calcium entry in microvascular cells. Peak calcium release was ∼40% lower in PMVECs than in PAECs, suggesting that either thrombin does not equivalently stimulate InsP~3~ production in both cell types or that InsP~3~ does not equivalently stimulate calcium release in PMVECs. Prior work supports the latter possibility; InsP~3~ is rapidly hydrolyzed in cytosol ([@bib55]) and we have recently demonstrated that the endoplasmic reticulum is twofold farther from the plasmalemma in PMVECs (∼250 nm) than in PAECs (∼100 nm) (unpublished data). Although not specifically examined in the present study, a decrease in thrombin-induced calcium release may result from hydrolysis of InsP~3~ before receptor binding. Although thrombin-induced calcium release was lower in PMVECs than in PAECs, the calcium entry response was ∼30% higher ([Fig. 3](#fig3){ref-type="fig"}). Thus, although calcium store depletion and calcium entry correlate within a cell type, the magnitude of calcium release and entry are not associated between cell types.

![**Coupling between Ca^2^** ^+^ **store depletion and activation of Ca^2^** ^+^ **entry is dissimilar between PAECs and PMVECs.** Whereas maximal thrombin-induced Ca^2+^ release is greater in PAECs, maximal Ca^2+^ entry is elevated in PMVECs (*n* = 3/treatment). An asterisk denotes significant difference from corresponding PAEC value.](0204022f3){#fig3}

Thrombin produces homologous desensitization of its receptor(s), resulting in decreased \[Ca^2+^\]i signaling, inhibition of protein phosphorylation, and preservation of endothelial cell barrier function ([@bib5]; [@bib37]; [@bib71]; [@bib36]; [@bib73]). Maximal or near-maximal thrombin doses are typically used for desensitization studies. We examined whether lower thrombin concentrations desensitize subsequent \[Ca^2+^\]i responses to EC~100~ thrombin concentrations. [Fig. 4, A, C, and D](#fig4){ref-type="fig"}, illustrates that an EC~20~ concentration of thrombin effectively desensitizes PAECs to subsequent activation by maximal doses. In PMVECs, similar low concentrations of thrombin only reduced the maximal response by 40%, indicating that 0.01 U/ml was insufficient to fully desensitize thrombin-induced \[Ca^2+^\]i signaling in microvascular cells. However, 0.1 U/ml thrombin induced a large \[Ca^2+^\]i rise and abolished the subsequent \[Ca^2+^\]i response to maximal thrombin concentrations in PMVECs ([Fig. 4](#fig4){ref-type="fig"}, B--D). Thus, thrombin-induced calcium entry is abolished by receptor desensitization, as it is in the presence of nominal extracellular calcium.

###### 

**Low thrombin concentrations acutely desensitize \[Ca^2^** ^+^ **\]i signaling.** (A) Application of an EC~20~ thrombin dose acutely abolishes the subsequent \[Ca^2+^\]i response to an EC~100~ thrombin concentration in PAECs. Similar inhibition was not observed in PMVECs (unpublished data). Units on the y axis scale represent the ratio of calcium-bound (340 nm) to -unbound (380 nm) wavelengths for fura-2 fluorescence. (B) Application of an EC~100~ thrombin concentration acutely reduces the subsequent \[Ca^2+^\]i response to a higher thrombin dose in PMVECs. Summary data are shown for Ca^2+^ release (C) and entry (D) phases, and are representative of *n* = 3/treatment. Area (AU, arbitrary units) on the y axis scale represents the relative area under the curve (e.g., above baseline values) generated during the Ca^2+^ entry phase.
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Thrombin-induced endothelial cell gap formation
-----------------------------------------------

Thrombin disrupts the endothelial cell barrier and increases macromolecular, solute, and water permeability ([@bib10]; [@bib44]; [@bib38]; [@bib24], [@bib25]; [@bib23]; [@bib2]; [@bib47]; [@bib51]). Barrier disruption is induced by an increase in centripetally directed tension that is mediated through the activation of an actomyosin-based motor, and by a decrease in cell adhesion that is mediated through the loss of cadherin-dependent cell--cell tethering. Signaling events that promote increased tension and decreased adhesion are incompletely understood, though calcium entry across the cell membrane is recognized as an important catalyst ([@bib46]). Despite the implied role of increased \[Ca^2+^\]i in the loss of endothelial cell barrier function, prior studies have not distinguished between \[Ca^2+^\]i-dependent signaling events and simultaneous activation of other signaling pathways, particularly in macro- and microvascular endothelia. We therefore examined the specific role of thrombin-induced calcium signaling in PAECs and PMVECs.

[Fig. 5](#fig5){ref-type="fig"} illustrates thrombin-induced gap formation in PAECs and PMVECs. Acute application of 1 U/ml (EC~100~) thrombin to PAEC monolayers produced small gaps between cells that resealed over a 1-h time course ([Fig. 5](#fig5){ref-type="fig"} A). Gaps were difficult to clearly resolve by light microscopy, though they were evident by the appearance of translucent cell--cell borders. These findings are compatible with prior studies indicating that increased macromolecular permeability occurs through only minor ultrastructural disturbances in adherens junctions ([@bib42]; [@bib50]). Higher thrombin concentrations (100 U/ml) produced larger, more visible intercellular gaps that persisted and, indeed, increased over a 2-h time course ([Fig. 5, B and D](#fig5){ref-type="fig"}). Because \[Ca^2+^\]i responses are lower in response to 100 U/ml than to 1 U/ml thrombin ([Fig. 1](#fig1){ref-type="fig"} D), these data indicate that the large gaps generated in response to higher thrombin concentrations occur after activation of calcium-independent signaling pathways.

###### 

**Thrombin induces interendothelial cell gap formation in PAECs and PMVECs, although only gaps in PMVECs reseal within 2 h.** (A) In basal PAEC monolayers (i), application of 1 U/ml thrombin induced intercellular gaps within 10 min (ii) that persisted over 60 (iii) and 120 (iv) min, though gaps were difficult to clearly resolve by light microscopy. Gaps are seen as translucent borders indicated by arrows in ii--iv. (B) To more clearly resolve gaps, PAECs were grown to confluence (i) and 100 U/ml thrombin was applied. Gaps apparent at 10 min (ii) were sustained over 30 (iii) and 60 (iv) min. (C) Application of 100 U/ml thrombin to PMVECs (i) resulted in the formation of large gaps at 10 min (ii) that were easily resolved. In contrast to PAECs, gaps in PMVECs resealed over 30 (iii) and 60 (iv) min. See Video 1, available at <http://www.jcb.org/cgi/content/full/jcb.200204022/DC1> *.* (D) Direct comparison of gaps between cell types reveals that whereas gap size increases temporally in PAECs, gap size decreases temporally in PMVECs. (E) The capacity of PMVECs to reseal their barrier is evident even when large gaps have formed. Arrows indicate intercellular gaps. *n* = 6--8/treatment.

![](0204022f5a)

![](0204022f5b)

![](0204022f5c)

![](0204022f5d)

![](0204022f5e)

Our prior studies indicated that direct activation of store-operated calcium entry did not increase PMVEC permeability ([@bib34]). Similarly, in the intact pulmonary circulation, thapsigargin did not induce intercellular gaps in small arteries, veins, or capillaries, but gap formation was prominent in large arteries and veins ([@bib13]). In our present study, thrombin (EC~100~) induced gap formation in cultured PMVECs, though unlike conduit cells, the response was not sustained ([Fig. 5](#fig5){ref-type="fig"}, C--E). Indeed, gaps that formed in PMVECs rapidly resealed; these findings are illustrated in the supplementary video (Video 1, available online at <http://www.jcb.org/cgi/content/full/jcb.200204022/DC1>) that accompanies [Fig. 5](#fig5){ref-type="fig"} C. A 1-h time course is compressed to ∼45 s in the video. Gaps were fully formed 5--10 min after thrombin application and subsequently resealed within 1--2 h.

Thrombin induced PAEC and PMVEC gaps that varied in size, though clearly the largest gaps were observed in PMVECs. A direct comparison between cell types is shown in [Fig. 5](#fig5){ref-type="fig"} D, where equivalent gap sizes are plotted. Whereas gap size progressively increased over 2 h in PAECs, gap size progressively decreased after 10 min in PMVECs. As shown in [Fig. 5](#fig5){ref-type="fig"} E, even the largest PMVEC gaps were nearly completely resealed by 2 h. These findings indicate that PMVECs possess a unique capacity to repair or reseal intercellular gaps, even in the continued presence of thrombin.

Calcium-sensitive ACs and endothelial cell gap formation
--------------------------------------------------------

Because thrombin activates multiple intracellular signaling cascades, we sought to examine the specific role of \[Ca^2+^\]i in gap formation. In PAECs, low thrombin concentrations (0.01 U/ml; EC~20~) desensitized the subsequent \[Ca^2+^\]i response to maximal doses (1.0 U/ml). In PMVECs, higher thrombin doses (0.10 U/ml) were required to desensitize subsequent \[Ca^2+^\]i responses. However, the use of higher concentrations elicited a large \[Ca^2+^\]i response and therefore the desensitization approach could not resolve between \[Ca^2+^\]i-dependent and -independent signal transduction pathways ([Fig. 6, A and B](#fig6){ref-type="fig"}), indicating that more direct approaches were required to specifically divulge the requirement of \[Ca^2+^\]i in thrombin-induced gap formation.

###### 

**A desensitizing thrombin concentration induces gap formation in PMVECs.** Application of 0.1 U/ml thrombin increased \[Ca^2+^\]i and desensitized the subsequent response to 10 U/ml thrombin ([Fig. 4](#fig4){ref-type="fig"} B). (A) Similar treatment in confluent PMVECs (i) revealed that the desensitizing \[Ca^2+^\]i response to 0.1 U/ml thrombin induced gap formation within 10 min (ii), which resolved over 30 (iii) and 60 (iv) min. (B) Summary of gaps formed by the desensitizing dose of thrombin shows resolution of gaps over a 60-min time course. Arrows indicate intercellular gaps. *n* = 3/treatment.
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Though Ca^2+^ entry is a well-recognized stimulus for endothelial cell barrier disruption, the Ca^2+^-sensitive targets mediating this response are poorly understood. We have previously reported that Ca^2+^ entry reduces cAMP in PAECs, and that the decrease in cAMP contributes to endothelial cell gap formation ([@bib63]). Indeed, the inverse relationship between Ca^2+^ and cAMP is mediated through AC~6~, which is specifically inhibited by Ca^2+^ entry through store-operated Ca^2+^ entry pathways ([@bib19], [@bib20], [@bib22]). Despite studies implicating AC~6~ in endothelial barrier disruption, conclusive proof for this idea has been limited by our inability to specifically control cAMP levels within the physiological range. The Ca^2+^-sensitive region of AC~6~ is unknown, and thus studies seeking to specifically eliminate enzyme Ca^2+^ inhibition are implausible ([@bib30]; [@bib29]). Our present approach therefore exploited an adenovirus vector constructed to express the Ca^2+^-stimulated AC~8~. Prior work from [@bib21] established that the AC~8~/adenovirus construct expresses functional enzyme that converts Ca^2+^ inhibition into Ca^2+^ stimulation of cAMP.

Expression of the AC~8~/adenovirus construct did not change basal PMVEC cAMP concentrations (control = 124 ± 9 fmol cAMP vs. AC~8~ = 120 ± 11 fmol cAMP). Forskolin and rolipram synergistically increase cAMP in PMVECs, and allow easy resolution of AC~6~ Ca^2+^ inhibition ([@bib65]; unpublished data). Similar to our previous reports ([@bib63], [@bib64], [@bib65]; unpublished data), thrombin inhibited cAMP in PMVECS that endogenously expressed AC~6~ ([Fig. 7](#fig7){ref-type="fig"} A). However, in cells expressing the AC~8~/adenovirus construct, the thrombin-induced Ca^2+^ inhibition was converted into Ca^2+^ stimulation of cAMP ([Fig. 7](#fig7){ref-type="fig"} B). Thus, cells infected with the AC~8~/adenoviral construct provided the first available model to specifically examine the physiological role of AC~6~ in regulation of endothelial cell barrier apposition.

###### 

**Expression of AC~8~ prevents thrombin from inducing gaps in PMVECs.** (A) Confluent PMVECs were incubated with the type 4 phosphodiesterase inhibitor rolipram (10 μM) for 10 min before thrombin (100 U/ml) treatment. 5 min after addition of thrombin, PMVECs were collected for cAMP determination. Thrombin decreased cAMP from 1293 ± 123 to 648 ± 37 fmol/well, consistent with calcium inhibition of endogenous AC~6~. (B) Expression of AC~8~ did not change basal cAMP concentrations. However, in cells infected with the AC~8~/adenovirus construct, rolipram (10 μM) and thrombin (100 U/ml) treatment resulted in an increase in cAMP, indicating that endogenous calcium inhibition had been converted to stimulation of AC. (C) Cells expressing the AC~8~/adenovirus construct (i) did not respond to thrombin with significant gap formation at 10 (ii), 30 (iii), or 60 (iv) min. Arrows indicate intercellular gaps. See Video 2, available at <http://www.jcb.org/cgi/content/full/jcb.200204022/DC1> *.*(D) Summary data reveals that thrombin induced few gaps in cells expressing the AC~8~/adenovirus construct. Gaps that did form were small in size and resealed rapidly (*n* = 7/treatment). (E) Cells expressing an alkaline phosphatase/adenovirus construct were used to confirm that adenoviral infection and expression, per se, did not provide nonspecific protection against thrombin-induced gap formation. Cells are shown before (i) and 10 (ii), 30 (iii), 60 (iv), and 90 (v) min after thrombin stimulation. Arrows indicate intercellular gaps. Video 3 demonstrates that expression of alkaline phosphatase does not inhibit thrombin-induced gap formation.
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Remarkably, infection with the AC~8~/adenoviral construct nearly abolished thrombin-induced PMVEC gap formation, shown in [Fig. 7, C and D](#fig7){ref-type="fig"}, and the accompanying time-compressed video (Video 2, available online at <http://www.jcb.org/cgi/content/full/jcb.200204022/DC1>). [Fig. 7](#fig7){ref-type="fig"} D summarizes all gaps formed in AC~8~-expressing cells treated with thrombin; this figure differs from control experiments (e.g., [Fig. 5](#fig5){ref-type="fig"} D) that standardized gap size between PAECs and PMVECs. Indeed, [Fig. 5](#fig5){ref-type="fig"} E illustrates PMVEC gaps that exceeded 15 × 10^2^ μm^2^ in some cases. Cells infected with the AC~8~/adenoviral construct possessed very few gaps that were of low magnitude (e.g., ≤2.4 × 10^2^ μm^2^). Although even small gaps rarely formed in cells expressing AC~8~, the video clearly illustrates that thrombin initiated cell movement. Thrombin induces myosin light chain phosphorylation and increases actomyosin motor function. The relative contributions of increased motor function and decreased cell adhesion to gap formation is still controversial. However, our data suggest cAMP primarily regulates adhesion as opposed to "contraction," and suggests that increased motor function does not form gaps if cell--cell adhesion is maintained.

It is not clear in AC~8~-expressing cells how small rises in global cAMP could, with such strength, oppose thrombin-induced gap formation. Recent studies ([@bib56], [@bib57]) implicate discrete cAMP pools, including its site of synthesis (e.g., plasmalemma) and the bulk cytosol, in location-specific function. Thus, AC localization is an important determinant of enzyme (and cAMP) function independent of global cAMP concentrations. We examined localization of AC~8~ by expressing it as a fusion with yellow fluorescent protein (YFP). [Fig. 8](#fig8){ref-type="fig"} illustrates nearly uniform expression of every cell infected with the YFP--AC~8~/adenoviral construct. Confocal imaging from abluminal-to-luminal cell aspects reveals punctate staining at abluminal and luminal cell aspects, with staining enrichment at cell--cell borders, suggesting that the enzyme localizes to sites of cell contact. Indeed, the video (Video 6) accompanying [Fig. 8](#fig8){ref-type="fig"} E demonstrates dynamic movement of YFP--AC~8~ at sites of cell--cell contact. As seen in this video, YFP--AC~8~ localization to cell--cell borders is retained in accordance with cell movement in response to thrombin, including membrane association during small, transient gap formation. Taken together, these data support the idea that AC localization to sites of cell--cell contact is an important determinant of how localized changes in calcium-dependent cAMP concentrations regulate intercellular gap formation.

###### 

**AC** ~8~ **localizes to sites of cell--cell contact.** (A) Subconfluent PMVECs (i) were infected with the YFP--AC~8~ adenovirus construct (ii). Overlay of phase contrast and fluorescent images (iii) reveals that virtually every cell expressed YFP--AC~8~. The box indicates cells analyzed by confocal microscopy in B--D. (B) Abluminal-to-luminal cell slices were analyzed by confocal microscopy at 0.5-μm resolution (i--xiv, abluminal to luminal). Punctate staining is observed on abluminal and luminal cell aspects, whereas staining enrichment was observed at cell--cell borders. Video 4 illustrates the abluminal-to-luminal expression pattern of YFP--AC~8~ *.* (C) Cell coordinates are shown on the x and y axes. Fluorescent intensity is shown on the z axis. Fluorescence intensity is greatest at sites of cell--cell contact. (D) 3-D reconstruction of confocal images taken in B demonstrates high fluorescent intensity at sites of cell--cell contact from side (i, arrow denotes AC~8~ expression at cell--cell borders and arrowhead denotes the cell\'s luminal aspect), angled (ii, arrowheads denote punctate staining), and horizontal (iii) views. Video 5 shows the lateral rotation of the 3-D image. (E) Response of YFP--AC~8~ was observed after application with thrombin (20 U/ml). Staining is most apparent at sites of cell--cell contact (i), and remains most intense at sites of cell--cell contact even after thrombin application for 10 (ii) and 30 (iii) min. Video 6 represents a compression of the 30-min thrombin response.
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Discussion
==========

Inflammatory \[Ca^2+^\]i agonists induce interendothelial cell gaps. However, a rise in \[Ca^2+^\]i only promotes gap formation if cAMP levels are not also increased. We have previously demonstrated that endothelial cells express AC~6~, and physiological \[Ca^2+^\]i transitions through store-operated calcium entry channels reduce enzyme activity ([@bib63], [@bib64], [@bib65]; unpublished data). In prior studies, activation of store-operated calcium entry decreased global cAMP by ∼30%. We have not firmly established whether a 30% decrease in global cAMP contributes to intercellular gap formation; indeed, because of difficulties regulating cAMP within a narrow concentration range, we have heretofore been unable to clearly establish the independent effects of \[Ca^2+^\]i and cAMP. Consequently, the physiological significance of AC~6~ was unclear. Use of an adenoviral construct expressing AC~8~ has allowed precise control over calcium-regulated cAMP production. For the first time, our findings directly implicate AC~6~ in thrombin-induced endothelial cell gap formation.

Emerging evidence suggests that PAECs and PMVECs arise from distinct embryological origins and retain phenotypic differences even when their environments are the same ([@bib18]; [@bib17]; [@bib66]; [@bib39]). Previous studies using these cells have demonstrated that their calcium and cyclic nucleotide regulatory properties significantly differ ([@bib64], [@bib65]), although they both possess store-operated calcium entry pathways and they both express AC~6~. PMVECs form a more restrictive barrier in vivo and in vitro to protect the alveolar-capillary network from fluid accumulation and to optimize gas exchange ([@bib34]; [@bib13]). Direct activation of store-operated calcium entry using thapsigargin increases PAEC, but does not increase PMVEC, macromolecular permeability ([@bib34]; [@bib13]). Our present studies therefore used the inflammatory \[Ca^2+^\]i agonist thrombin, which, like thapsigargin, activates store-operated calcium entry. In addition, however, thrombin activates G~i~ and G~12/13~ signaling pathways that inhibit AC ([@bib5]) and activate Rho signaling cascades ([@bib69]; [@bib7]; [@bib8]; [@bib58]; [@bib67],[@bib68]; [@bib72]), respectively. Activation of Rho and its kinase promotes the cytoskeletal reorganization that is important for induction of intercellular gap formation.

We found that thrombin induces gap formation in both PAECs and PMVECs. High thrombin concentrations were required to break cell--cell adhesions in microvascular cells. Indeed, our dose response curves were conducted over thrombin concentrations that exceeded its normal range. High thrombin concentrations revealed unique responses in PAECs and PMVECs. Calcium regulatory mechanisms are different between these cell types at high thrombin concentrations; PAECs posses a feedback inhibitory mechanism not present in PMVECs. In addition, gap formation in PAECs was slow and progressive, whereas gap formation in PMVECs was rapid and quickly resolved, suggesting that microvascular cells possess a motility/repair mechanism not present in their macrovascular counterparts. The gaps that formed in PMVECs were substantially larger than those present in PAECs. While speculative, PMVECs may possess a higher resting tension so that the disruption of cell--cell adhesion produces large gaps that form rapidly.

In PAECs, gaps formed in response to the high thrombin concentrations that also inhibited calcium entry. Thus, intercellular gap formation can be induced by \[Ca^2+^\]i-independent as well as \[Ca^2+^\]i-dependent signaling cascades. AC~6~ is a calcium entry--sensitive target that coordinates \[Ca^2+^\]i and cAMP signaling pathways. AC~6~ functionally colocalizes with store-operated calcium entry channels ([@bib19], [@bib20], [@bib22]), indicating that thrombin may inhibit AC~6~ activity by stimulating calcium entry and activating G~i~.

Our present studies sought to specifically determine the relevance of AC~6~ in thrombin-induced gap formation. Despite the activation of multiple signaling pathways, we found that converting calcium inhibition to modest stimulation of cAMP nearly abolished thrombin-induced gap formation in PMVECs. In AC~8~-expressing cells, AC~8~ localized to sites of cell--cell contact. Digitally time-compressed videos revealed that although AC~8~-expressing cells did not form gaps, they still exhibited significant movement that was generally consistent with activation of motor function. It therefore appears that AC~6~ decreases the cAMP necessary to break cell--cell adhesions without significantly altering actomyosin function per se. cAMP activation of its protein kinase reduces endothelial cell myosin light chain kinase activity ([@bib26]), indicating that cAMP is capable of reducing endothelial cell motor function. However, our findings suggest that the principal role of calcium-sensitive cAMP synthesis is not to regulate actomyosin interaction, but rather to control cell--cell adhesion. In future studies, it will be important to determine relevant A-kinase targets that may control development of intercellular gap formation.

In summary, our studies have used two distinct endothelial cell phenotypes, PAECs and PMVECs, to evaluate the role of AC~6~ in thrombin-induced gap formation. Thrombin activates store-operated calcium entry in both cell types, along with other reported signaling cascades. Nonetheless, calcium entry across the cell membrane is an important determinant of gap formation. We have established for the first time that calcium entry is required to inhibit AC~6~ activity, which decreases cAMP necessary for generation of intercellular gaps. These findings firmly establish a physiological role for AC~6~ in nonexcitable endothelial cells: AC~6~ critically regulates gap formation.

Materials and methods
=====================

Reagents
--------

All reagents were obtained from Sigma-Aldrich, unless otherwise specified. Thrombin used in calcium and videomicroscopy experiments was from Sigma-Aldrich, catalog no. T-6634, lot 19H7612 (from bovine plasma) or catalog no. T-5772, lot 71K7612 (from rat plasma). Fura-2/AM and Pluronic^®^ F-127 were purchased from Molecular Probes.

Isolation and culture of pulmonary endothelial cells
----------------------------------------------------

PAECs and PMVECs were isolated and cultured using a method described in detail by [@bib65]. Cells were routinely passaged by scraping. Cultures were characterized using SEM, uptake of 1,1\'-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine--labeled low-density lipoprotein (DiI-acetylated LDL), and a lectin binding panel.

Construction of the virus expressing AC~8~
------------------------------------------

A full-length description of the adenovirus expressing AC~8~ has been reported in detail elsewhere ([@bib21]). However, for construction of an adenovirus-transducing vector encoding the YFP--AC~8~ fusion protein, the YFP--AC~8~ fusion protein gene was excised from the plasmid pEYFP-C1 by digesting with NheI, filling in with T4 DNA polymerase in the presence of dNTPs, and digesting with XbaI. The plasmid pShuttleCMV ([@bib31]) was digested with XhoI, blunt ended with T4 DNA polymerase in the presence of dNTPs, and digested with XbaI. The YFP--AC~8~ gene and pShuttleCMV fragments were resolved by low melting point agarose gel electrophoresis, excised, and the DNA fragments were recovered by melting the agarose followed by phenol extraction and ethanol precipitation. The DNA fragments were ligated to generate the plasmid pShuttleCMV-YFP--AC~8~. The YFP--AC~8~ gene was removed from pShuttleCMV-YFP--AC~8~ by digestion with NotI and XbaI and ligated with pShuttleE1A DNA ([@bib59]) that had been digested with the same restriction enzymes. The shuttle vectors encoding YFP--AC~8~ were then linearized by digestion with PmeI, and 20 ng of each was used to electroporate *Escherichia coli* strain BJ5183 carrying the plasmid pAdEasy-1([@bib31]), a modification that we previously found helpful for plasmid construction ([@bib53]), to introduce the YFP--AC~8~ genes into the adenovirus chromosome by homologous recombination ([@bib11]; [@bib15]; [@bib31]). Resulting colonies were screened by agarose gel electrophoresis of undigested plasmid DNAs. Supercoiled plasmids that migrated slower than linear 12-kb marker DNA were then used to transform *E. coli* DH5, and the plasmids tested by restriction digestion, and grown in large scale. The resulting plasmids were named pAdEasyCMV-YFP--AC~8~ and pAdEasyE1A-YFP--AC~8~. The plasmid DNAs were digested with PacI to liberate the adenovirus chromosomes and used to transfect ([@bib32]) 293 cells ([@bib28]) to make viruses. Despite repeated attempts, no plaques were isolated from cells transfected with pAdEasyCMV-YFP--AC~8~. However, fluorescent plaques were readily obtained from cells transfected with pAdEasyE1A-YFP--AC~8~, suggesting that the level of overexpression of the YFP--AC~8~ gene that results from the use of the CMV major immediate early promoter inhibited virus production ([@bib59]). AdEasyE1A-YFP--AC~8~ virus was plaque purified and grown in large scale using 293 cells, purified by successive banding on CsCl step and isopycnic gradients, and dialyzed using three changes of 10 mM Tris-HCl, pH 8.0, 135 mM NaCl, 1 mM MgCl~2~, 50% vol/vol glycerol at 4°C. The particle concentration of the virus was quantitated by determination of the absorbance at 260 nm, where one A~260~ unit was considered equal to 10^12^ virus particles. The particle/plaque forming unit ratio for viruses prepared in this manner is reproducibly close to 100:1. The virus was stored at −20°C.

Infection with adenovirus/AC~8~ construct
-----------------------------------------

PMVECs were seeded onto 25-mm glass coverslips and grown to ∼60% confluence, at which point they were infected with the adenoviral vector constructed to express Ca^2+^-stimulated AC~8~ at a titer of 100 plaque forming units/cell. Initial studies using PAECs (unpublished data) and GH4C1 cells established a dose-dependent increase in calcium-dependent cAMP synthesis over a multiplicity of infection range from 0 to 200. A multiplicity of infection of 100 provided reproducible calcium-stimulated cAMP responses and was therefore selected as the dose used in our present studies. Cells were used 48 h after infection for cAMP measurement and videomicroscopy studies.

Calcium measurement
-------------------

Calcium measurements and endothelial cell calibrations have been described elsewhere ([@bib62]).

cAMP measurements
-----------------

cAMP content was determined using a Biotrack cAMP competitive enzyme-immunoassay system (Amersham Pharmacia Biotech).

Confocal fluorescence microscopy
--------------------------------

Fluorescent images were acquired on a Leica TCS SP2 confocal laser scanning microscope at a 514-nm excitation. Slices were taken through cells at 0.5-μm sections.

Time-lapsed fluorescence microscopy
-----------------------------------

40--48 h after infection with the YFP--AC~8~ construct, media was removed from cells and replaced with Krebs/2 mM Ca^2+^ buffer. Fluorescent images were acquired on an Olympus IX70 inverted microscope at 488-nm excitation and processed using Spot Software (Diagnostic Instruments). Time-lapse experiments were performed using the MetaMorph^®^ (Universal Imaging Corp.) system. Images were collected at 40-s intervals over 30 min.

Online supplemental material
----------------------------

Supplemental videos are available at <http://www.jcb.org/cgi/content/full/jcb.200204022/DC1>. Videos 1--3 are time-compressed movies of PMVECs, demonstrating that thrombin-induced gap formation occurs only when arise in \[Ca^2+^\] reduces cAMP. Videos 4--6 illustrate localization of AC (YFP--AC~8~) primarily at sites of cell--cell adhesion.
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